Effects of food containing Lactococcus lactis strain T21 on the improvement of skin condition: a randomized, double-blind, placebo-controlled, parallel-group study
- PMID: 39364129
- PMCID: PMC11444856
- DOI: 10.12938/bmfh.2023-086
Effects of food containing Lactococcus lactis strain T21 on the improvement of skin condition: a randomized, double-blind, placebo-controlled, parallel-group study
Abstract
This research aimed to examine the effect of daily intake of food containing Lactococcus lactis strain T21 (T21) on skin conditions and inflammation-related markers in healthy adults who experience itching because of dry skin and have an atopic predisposition. A randomized, double-blind, placebo-controlled parallel-group study was conducted on 44 subjects aged 20 to 64 years. Subjects were randomly assigned to receive a T21-containing food or placebo daily for 8 weeks. The hydration of stratum corneum, trans-epidermal water loss, skin brightness (L*), skin redness (a*), and quality of life (QOL) scores were evaluated. Moreover, SCCA2, Th1/Th2, peripheral blood eosinophil count, TGF-β1, TARC, total IgE, and LDH were measured as inflammation-related markers. The results showed that, compared with the placebo, food containing T21 reduced trans-epidermal water loss in the neck and increased neck skin brightness (L*) after 8 weeks of consumption. Furthermore, a stratified analysis in subjects with a history of atopy showed improvements in neck skin redness (a*) and skin-related QOL. No significant improvement in inflammation-related markers was observed. Intake of food containing T21 for 8 weeks in healthy adult with atopic predisposition was suggested to improve skin barrier function in the neck and brightness in the neck skin. Furthermore, the results also suggested that it had the effect of improving rough skin and reducing discomfort due to dryness in healthy adults with a history of atopy.
Keywords: Lactococcus lactis strain T21; inflammation-related marker; lactic acid bacteria; quality of life; skin condition; trans-epidermal water loss.
©2024 BMFH Press.
Conflict of interest statement
Nissin Food Holdings Co., Ltd. provided the research funds and test foods (T21 and placebo) for this study, which was properly conducted by a third-party organization, EP Mediate Co., Ltd. Sumio Kondo at Fukushima Health Care Center was the principal investigator of this study; he has no conflicts of interest to disclose despite having performed commissioned work. There were no other conflicts of interest to be noted.
Figures



Similar articles
-
Safety and Efficacy of Oral Intake of Ceramide-Containing Acetic Acid Bacteria for Improving the Stratum Corneum Hydration: A Randomized, Double-Blind, Placebo-Controlled Study over 12 Weeks.J Oleo Sci. 2020 Nov 1;69(11):1497-1508. doi: 10.5650/jos.ess20115. Epub 2020 Oct 15. J Oleo Sci. 2020. PMID: 33055441 Clinical Trial.
-
Oral intake of heat-killed cells of Lactococcus lactis strain H61 promotes skin health in women.J Nutr Sci. 2012 Dec 6;1:e18. doi: 10.1017/jns.2012.22. eCollection 2012. J Nutr Sci. 2012. PMID: 25191547 Free PMC article.
-
Improvement of skin conditions by ingestion of Aspergillus kawachii (Koji) extract containing 14-dehydroergosterol in a randomized, double-blind, controlled trial.Clin Cosmet Investig Dermatol. 2018 Mar 9;11:115-124. doi: 10.2147/CCID.S152979. eCollection 2018. Clin Cosmet Investig Dermatol. 2018. PMID: 29563825 Free PMC article.
-
Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care settings.Cochrane Database Syst Rev. 2020 Jan 23;1(1):CD011377. doi: 10.1002/14651858.CD011377.pub2. Cochrane Database Syst Rev. 2020. PMID: 32006460 Free PMC article.
-
Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.Treat Respir Med. 2004;3(4):247-68. doi: 10.2165/00151829-200403040-00005. Treat Respir Med. 2004. PMID: 15350163 Review.
Cited by
-
Genomic Insights into Probiotic Lactococcus lactis T-21, a Wild Plant-Associated Lactic Acid Bacterium, and Its Preliminary Clinical Safety for Human Application.Microorganisms. 2025 Feb 10;13(2):388. doi: 10.3390/microorganisms13020388. Microorganisms. 2025. PMID: 40005754 Free PMC article.
References
-
- Tanemono S, Sujino T, Kanai T. 2017. Relationship between intestinal flora and immunity. Jpn J Clin Immunol 40: 408–415.
-
- Izawa Y, Noma T, Yamamoto M, Kimura K, Ito H, Taketomo N, Numano K, Kawashima M. 2008. Verification of the effect of yogurt using LB81 lactobacillus on skin function improvement. Chonai Saikingaku Zasshi 22: 1–5.
-
- Yoshikawa K, Aota K, Takada Y, Nakamura T, Hoshino T, Yamashita S, Takara T. 2018. Effect of Lactobacillus brevis SBC8803 (SBL88TM lactobacillus) intake on improving sleep quality—a randomized, placebo-controlled, double-blind, parallel-group study. Jpn Pharmacol Ther 46: 1723–1738.
-
- Nakagawa K, Koda T, Hamada K, Sugaya T, Saito T. 2020. Application of Lactobacillus B240 as a conditioning food for mucosal immune support and anti-infective effect. J Nutr Sci Vitaminol (Tokyo) 73: 55–60.
-
- Suzuki H. 2015. Effects of consumption of a beverage containing Lactococcus lactis subsp. lactis JCM5805 on antiviral immune response and maintenance of physical condition—a placebo-controlled, randomized, double-blind, parallel-group comparison study—. Jpn Pharmacol Ther 43: 1465–1472.